• Scarless Circular mRNA CAR-T: Study Insights

  2026-09-15

  Hu and colleagues developed a permuted intron exon platform for producing scarless circular mRNAs that sustain CAR expression more effectively than linear mRNAs in primary human T cells. The resulting circular-mRNA CAR-T cells showed stronger antigen-specific activity, favorable activation-associated transcriptomic profiles, and improved antitumor effects in vivo, while retaining the controllability of a nonintegrating modality.

• Imatinib Hydrochloride: State-Aware Assays

  2026-09-15

  Imatinib hydrochloride is more than an ATP-site blocker: its target profile can be used to design interpretable leukemia and GIST experiments. This article connects practical assay design with new evidence on kinase conformation and phosphatase-accessible states.

• LPS Protects Macrophages via System Xc− and ABCC1

  2026-09-14

  A 2026 study examined how lipopolysaccharide protects macrophages from antitumor drug toxicity without producing the same protection in tumor cells. Its results connect LPS exposure with system Xc−-dependent glutathione synthesis and ABCC1-associated drug transport, while also highlighting the need for orthogonal validation of pharmacological inhibitor data.

• Sulfo-NHS-SS-Biotin: Reversible Surface Labeling

  2026-09-14

  Sulfo-NHS-SS-Biotin is a water-soluble, amine-reactive reagent for reversible protein and cell-surface labeling. Its cleavable disulfide spacer supports streptavidin-based enrichment while allowing reducing-condition release of the biotin tag from labeled targets.

• Relative Viability vs Cell Killing in Cancer Assays

  2026-09-13

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that drug-induced growth inhibition and cell death are related but not interchangeable responses. The framework supports more rigorous cancer pharmacology by combining endpoint selection with temporal analysis rather than interpreting a single viability measurement as definitive evidence of apoptosis.

• MK-0812 for CCR2 Assay Reliability

  2026-09-12

  This scenario-driven guide explains how MK-0812, SKU A3611, can help researchers distinguish CCR2-dependent monocyte trafficking from nonspecific viability or cytotoxicity effects. It combines product-linked potency data, practical DMSO handling, assay controls, and gut–liver inflammation context for more interpretable experiments.

• Dorsomorphin 2HCl: From AMPK Proof to Translation

  2026-09-11

  Dorsomorphin 2HCl is more than an AMPK inhibitor: it is a mechanistic probe for linking metabolic, BMP, osteogenic, and iron-regulatory biology to translational decisions.

• AO/PI Double Staining Kit: Practical Guide

  2026-09-11

  The AO/PI Double Staining Kit provides a rapid fluorescent cell viability assay that separates predominantly viable, apoptotic, and membrane-compromised cell populations in one staining workflow. It is suitable for screening and comparative cell-death measurements, but it should not be used alone to establish a specific apoptosis pathway or replace orthogonal validation.

• Caspase-3 Fluorometric Assay Kit in Ferroptosis

  2026-09-10

  Learn how the Caspase-3 Fluorometric Assay Kit can separate executioner-caspase activation from broader ferroptosis signals. This evidence-led guide uses recent PARP1 research to improve caspase activity measurement and experimental interpretation.

• FITC-Concanavalin A (ConA) Conjugate Guide

  2026-09-10

  FITC-Concanavalin A (ConA) Conjugate is a fluorescent lectin probe for visualizing accessible α-D-glucose and α-D-mannose residues on glycoproteins and glycolipids in cell or tissue samples. It is suited to carbohydrate-focused immunofluorescence staining and flow cytometry, but it should not be used as a protein-specific antibody or a universal stain for non-carbohydrate targets.

• ATRA Reverses Cisplatin-Induced PARP Resistance

  2026-09-09

  This study shows that all-trans retinoic acid (ATRA) can reduce cisplatin-induced resistance to PARP inhibition in epithelial ovarian cancer. By combining ATRA with niraparib after cisplatin exposure, the authors connect treatment sequencing to suppression of an NAD+-associated resistance program involving ALDH1A1, NAMPT, PARP1, and CHK1.

• 7-Ethyl-10-hydroxycamptothecin Workflow

  2026-09-09

  Build mechanism-first SN-38 experiments that connect topoisomerase I poisoning with DNA damage, cell-cycle profiling, apoptosis, and FUBP1–FUSE biology. This workflow helps advanced colon cancer research move beyond single-endpoint viability assays while addressing solubility, dosing, and reproducibility challenges.

• Salvianolic acid B: Reliable Cell Assays

  2026-09-08

  This scenario-driven guide explains how Salvianolic acid B can improve interpretation of viability, proliferation, and pulmonary fibrosis assays. It connects SKU N1806 specifications with practical controls, dosing, readout validation, and vendor-selection criteria for reproducible research workflows.

• Streptavidin-FITC: Fluorescent Biotin Detection

  2026-09-08

  Streptavidin-FITC is a fluorescein isothiocyanate conjugated streptavidin reagent for detecting biotinylated proteins, antibodies, nucleic acids, and other biomolecules. Its tetrameric binding architecture and FITC fluorescence support immunohistochemistry, immunofluorescence, flow cytometry, and nucleic acid trafficking workflows.

• Butylhydroxyanisole (BHA) for Oxidative Stress Assays

  2026-09-07

  Butylhydroxyanisole (BHA) gives researchers a controllable way to probe free-radical biology across ROS, viability, and apoptosis workflows. This guide emphasizes solvent discipline, timing controls, orthogonal readouts, and practical lessons from peptide research that improve assay interpretation.

7981 records 1/533 page Next 12345 下5页 Last page